Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma

Soledad Henriquez; Jérémie Zerbit; Timothée Bruel; Amani Ouedrani; Delphine Planas; Paul Deschamps; Isabelle Staropoli; Jérôme Hadjadj; Bruno Varet; Natalia Ermak; Didier Bouscary; Lise Willems; Guillemette Fouquet; Justine Decroocq; Patricia Franchi; Benedicte Deau-Fischer; Benjamin Terrier; Jérôme Tamburini; Lucienne Chatenoud; Olivier Schwartz; Marguerite Vignon

doi:10.1182/blood.2021013714

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma

Blood. 2022 Feb 10;139(6):942-946. doi: 10.1182/blood.2021013714.

Authors

Soledad Henriquez¹, Jérémie Zerbit², Timothée Bruel^{3

4}, Amani Ouedrani^{5

6}, Delphine Planas^{3

4}, Paul Deschamps⁷, Isabelle Staropoli³, Jérôme Hadjadj¹, Bruno Varet⁸, Natalia Ermak⁹, Didier Bouscary^{7

10}, Lise Willems⁷, Guillemette Fouquet⁷, Justine Decroocq⁷, Patricia Franchi⁷, Benedicte Deau-Fischer⁷, Benjamin Terrier^{1

11}, Jérôme Tamburini^{7

12}, Lucienne Chatenoud^{5

6

13}, Olivier Schwartz^{3

4}, Marguerite Vignon⁷

Affiliations

¹ Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases.
² Department of Clinical Pharmacy, Assistance Publique-Hôpitaux de Paris.Centre-Université de Paris (AP-HP.CUP), Hôpital Cochin, Paris, France.
³ Virus and Immunity Unit, Department of Virology, Institut Pasteur; Centre National de la Recherche Scientifique, Unite Mixte de Recherche (CNRS UMR) 3569, Paris, France.
⁴ Vaccine Research Institute, Créteil, France.
⁵ Department of Biological Immunology, Assistance Publique-Hôpitaux de Paris.Centre-Université de Paris (AP-HP.CUP), Hôpital Necker-Enfants Malades, Paris, France.
⁶ Université de Paris, CNRS UMR 8253 and INSERM UMR 1151, Institut Necker-Enfants Malades, Paris, France.
⁷ Department of Clinical Hematology, Assistance Publique-Hôpitaux de Paris.Centre-Université de Paris (AP-HP.CUP), Hôpital Cochin, Paris, France.
⁸ Department of Adult Hematology, Assistance Publique-Hôpitaux de Paris.Centre-Université de Paris (AP-HP.CUP), Hôpital Necker-Enfants Malades, Paris, France.
⁹ Department of Biological Immunology, Assistance Publique-Hôpitaux de Paris.Centre-Université de Paris (AP-HP.CUP), Hôpital Cochin, Paris, France.
¹⁰ Université de Paris, CNRS UMR 8104, INSERM U1016, Institut Cochin, Paris, France.
¹¹ Université de Paris, INSERM, U970, Paris Cardiovascular Research Center, Paris, France.
¹² Université de Genève, Couverture Maladie Universelle, Genève, France; and.
¹³ Université Paris Descartes, Paris, France.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

ADP-ribosyl Cyclase 1 / antagonists & inhibitors*
ADP-ribosyl Cyclase 1 / immunology
Adult
Aged
Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use*
BNT162 Vaccine / pharmacology
BNT162 Vaccine / therapeutic use*
COVID-19 / complications
COVID-19 / immunology
COVID-19 / prevention & control*
Female
Humans
Immunity, Cellular
Immunity, Humoral
Immunogenicity, Vaccine
Male
Middle Aged
Multiple Myeloma / complications
Multiple Myeloma / drug therapy*
Multiple Myeloma / immunology
Prospective Studies
SARS-CoV-2 / immunology*

Substances

Antineoplastic Agents, Immunological
ADP-ribosyl Cyclase 1
BNT162 Vaccine

Supplementary concepts

SARS-CoV-2 variants